Enrique Aranda Selected Research

Enrique Aranda Research Topics

Disease

39	Colorectal Neoplasms (Colorectal Cancer) 06/2022 - 03/2005
33	Neoplasms (Cancer) 06/2022 - 05/2005
11	Neoplasm Metastasis (Metastasis) 09/2021 - 01/2008
11	Adenocarcinoma 02/2021 - 06/2009
7	Breast Neoplasms (Breast Cancer) 01/2021 - 06/2008
6	Rectal Neoplasms (Rectal Cancer) 11/2020 - 09/2006
5	Colonic Neoplasms (Colon Cancer) 10/2020 - 07/2009
4	Disease Progression 09/2021 - 01/2012
4	Pancreatic Neoplasms (Pancreatic Cancer) 03/2021 - 01/2017
4	Diarrhea 01/2012 - 03/2005
3	Lung Neoplasms (Lung Cancer) 02/2021 - 01/2016
3	Carcinoma (Carcinomatosis) 01/2018 - 09/2011
3	Ovarian Neoplasms (Ovarian Cancer) 07/2011 - 09/2006
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 02/2021 - 01/2018
2	Stomach Neoplasms (Stomach Cancer) 01/2021 - 08/2009
2	Hypertension (High Blood Pressure) 11/2018 - 12/2015
2	Exanthema (Rash) 01/2017 - 11/2016
2	Sarcoma (Soft Tissue Sarcoma) 01/2017 - 12/2013
2	Circulating Neoplastic Cells 12/2013 - 01/2012
2	Hand-Foot Syndrome 01/2012 - 09/2007
2	Peritoneal Neoplasms 07/2011 - 09/2006
2	Neutropenia 07/2009 - 03/2005
1	Fatigue 01/2022
1	Sleep Initiation and Maintenance Disorders (Insomnia) 01/2022
1	Respiratory Tract Diseases (Respiratory Tract Disease) 02/2021
1	Pain (Aches) 01/2021
1	Microsatellite Instability 01/2020
1	Inflammation (Inflammations) 12/2019
1	Carcinogenesis 01/2019
1	Dysphonia (Spastic Dysphonia) 11/2018
1	Asthenia 11/2018

Drug/Important Bio-Agent (IBA)

17	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2021 - 03/2005
16	Bevacizumab (Avastin)FDA Link 06/2022 - 01/2012
15	Fluorouracil (Carac)FDA LinkGeneric 01/2022 - 03/2005
13	Irinotecan (Camptosar)FDA LinkGeneric 01/2022 - 05/2005
12	Capecitabine (Xeloda)FDA Link 01/2021 - 09/2007
8	Biomarkers (Surrogate Marker)IBA 01/2022 - 12/2015
6	Cetuximab (Erbitux)FDA Link 01/2021 - 01/2012
6	Proteins (Proteins, Gene)FDA Link 12/2019 - 06/2009
5	Leucovorin (Folinic Acid)FDA Link 01/2022 - 03/2005
5	Trastuzumab (Herceptin)FDA Link 01/2021 - 08/2009
5	XELOXIBA 01/2012 - 09/2007
4	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2021 - 10/2018
4	Cisplatin (Platino)FDA LinkGeneric 01/2018 - 08/2009
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 06/2022 - 11/2011
3	MicroRNAs (MicroRNA)IBA 01/2022 - 02/2021
3	Biological ProductsIBA 01/2021 - 03/2011
3	ErbB Receptors (EGF Receptor)IBA 01/2020 - 12/2015
3	CateninsIBA 10/2018 - 01/2015
3	Messenger RNA (mRNA)IBA 12/2015 - 06/2009
3	Paclitaxel (Taxol)FDA LinkGeneric 07/2011 - 09/2006
2	Pharmaceutical PreparationsIBA 01/2022 - 11/2016
2	Biosimilar PharmaceuticalsIBA 11/2021 - 01/2021
2	regorafenibIBA 04/2021 - 11/2018
2	Estrogen ReceptorsIBA 01/2021 - 12/2012
2	Gemcitabine FDA Link 11/2020 - 01/2017
2	Panitumumab (Vectibix)FDA Link 01/2019 - 01/2017
2	Protein Isoforms (Isoforms)IBA 10/2018 - 01/2014
2	Celecoxib (Celebrex)FDA Link 03/2017 - 01/2015
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2017 - 11/2016
2	Tyrosine Kinase InhibitorsIBA 11/2016 - 01/2015
2	S-NitrosothiolsIBA 01/2016 - 12/2012
2	DNA (Deoxyribonucleic Acid)IBA 12/2015 - 01/2014
2	thiamine triphosphorate (TTP)IBA 06/2008 - 09/2007
1	4-amino-4'-hydroxylaminodiphenylsulfone (HADS)IBA 01/2022
1	afliberceptIBA 01/2022
1	trifluridine tipiracil drug combinationIBA 09/2021
1	Alkaline PhosphataseIBA 09/2021
1	Tamoxifen FDA LinkGeneric 01/2021
1	Estrogens (Estrogen)FDA Link 01/2021
1	130-nm albumin-bound paclitaxelIBA 11/2020
1	Cell-Free Nucleic AcidsIBA 07/2020
1	Glucose (Dextrose)FDA LinkGeneric 01/2020
1	LigandsIBA 01/2020
1	Glutamine (L-Glutamine)FDA Link 01/2020
1	Lapatinib (GW572016)FDA Link 01/2020
1	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2020
1	Chemokine ReceptorsIBA 01/2020
1	ChemokinesIBA 01/2020
1	Ribosomal Proteins (Ribosomal Protein)IBA 12/2019
1	4- (4- dihexadecylaminostyryl)- N- methylpyridium (DiA)IBA 12/2019
1	Histone Deacetylase 2IBA 12/2019
1	OsteopontinIBA 12/2019
1	Complement System Proteins (Complement)IBA 12/2019
1	Dihydrotachysterol (AT 10)IBA 12/2018
1	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 10/2018
1	2- phenyl- 4,4,5,5- tetramethylimidazoline- 1- oxyl- 3- oxideIBA 10/2018
1	Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA 10/2018
1	IsoenzymesIBA 10/2018
1	Axitinib (AG 013736)IBA 01/2018

Therapy/Procedure

25	Therapeutics 06/2022 - 01/2006
24	Drug Therapy (Chemotherapy) 06/2022 - 05/2005
5	Radiotherapy 11/2020 - 09/2006
5	Chemoradiotherapy 11/2020 - 09/2006
2	Drug Tapering 09/2021 - 11/2018
2	Immunotherapy 01/2020 - 01/2019
2	Hyperthermic Intraperitoneal Chemotherapy 01/2018 - 07/2011
1	Precision Medicine 02/2021
1	Salvage Therapy 01/2019
1	Duration of Therapy 11/2018